Navigation Links
Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO
Date:5/28/2009

MELBOURNE, Australia, May 28 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) announced that it will present preliminary data from its Phase I clinical trial of orally administered CYT997, at the Annual Meeting of the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.

Dr Alessandra Francesconi, one of the clinical investigators for the program, will be presenting the poster in the Developmental Therapeutics - Vascular Targeting poster session on Saturday 30th May from 8:00 AM to 12:00 PM (US EST), Level 2, West Hall C.

The poster entitled "Phase I evaluation of orally-administered CYT997, a novel cytotoxic vascular-disrupting agent, in patients with advanced cancer" details safety, tolerability and preliminary activity findings from this study, which concluded in February 2009. CYT997 is currently undergoing further clinical investigation in Phase II studies in relapsed glioblastoma multiforme and multiple myeloma.

Enquiries


    Dr. Gregg Smith                            Mr. Andrew Macdonald
    Director, Drug Development and Operations  Chief Executive Officer
    T: +61 3 9208 4234                         T: +61 3 9208 4232
    gregg.smith@cytopia.com.au                 andrew.macdonald@cytopia.com.au

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat
'/>"/>

SOURCE Cytopia Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cytopia Presentation on VDA CYT997 at AACR Conference
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... AZ (PRWEB) August 19, 2014 Sales ... launch of its online sales skills training course ... sales skills. , MedTech clinical staff spend the majority ... a hospital, standalone medical center, or physician practice – ... staff. But why stop there? Sales Horizons believes clinical ...
(Date:8/18/2014)... Aug. 18, 2014 BioElectronics Corporation ... consumer medical devices said that its EVP ... by CEOLIVE.TV as part of its Executive ... is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... to investors the unique advantages of BioElectronics ...
(Date:8/18/2014)... , August 18, 2014 ... Transparency Market Research "Life Science Reagents Market(Products- PCR ... Electrophoresis, Chromatography, In-Vitro Diagnostic Reagents and Others; End ... Institutions, Clinical Laboratories, and Forensic Laboratories)- Global Industry ... - 2019", the global life science reagents market ...
(Date:8/18/2014)... Toronto, Canada (PRWEB) August 18, 2014 ... land of opportunity for the clinical research industry. ... clinical trials due to its aging population; a ... in chronic diseases; a densely populated pool of ... enrolment. , Notwithstanding these positive points, China also ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
(Date:8/19/2014)... From this week,s Eos: Long-Term Ecological Research and Network-Level ... track how a wide range of ecosystems was responding ... would be particularly powerful if it coupled multiple decades ... large-scale, long-term experiments and models from dozens of different ... It is the Long-Term Ecological Research (LTER) Network, which ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... A new study published this week in the journal ... mixing of cold, deep waters from below can change sea ... occurs in a huge region of the ocean that takes ... climate patterns, particularly global warming. Using a new measurement ...
... cell found in the trillions in our brain have made ... injury and disease such as stroke. A University of Bristol ... how astrocyte cells respond to neurological trauma. The star-shaped ... glial cell that comprise one of two main categories of ...
... research team from the School of Basic Medical ... Radix Achyranthis Bidentatae can inhibit advanced glycation end ... cortex, and improve learning and memory capabilities in ... on advanced glycation end product accumulation is associated ...
Cached Biology News:Study explains Pacific equatorial cold water region 2Study explains Pacific equatorial cold water region 3Key target responsible for triggering detrimental effects in brain trauma identified 2
... a serine/threonine phosphatase isolated from human red ... heterodimer of 60kDa (A) and 36kDa (C) ... the a-subunit of phosphorylase kinase. With its ... specificity and may play a regulatory role ...
... Monitoring Kit measures adenosine triphosphate ... and a dynamic range. Based ... assay measures ATP in bacterial, ... a concentration range of 10-11 ...
... Jouan RCT series of refrigerated cold traps ... trapping of low volatility/aqueous solvents or high ... and other vacuum concentrators/centrifugal evaporators. Also used ... systems such as used in electron microscopes. ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: